Urothelial Carcinoma

Oncology·MeSH: Carcinoma, Transitional Cell

Prevalence

5.0 / 100K

57 drugs in development·24 companies·46 clinical trials

Drug Pipeline by Phase

Phase 3(20)

Drug	Company
Apalutamide	Myovant Sciences Ltd. (MYOV)
Apalutamide	Crinetics Pharmaceuticals, Inc. (CRNX)
avelumab	GH Research PLC (GHRS)
Avelumab	Royalty Pharma plc (RPRX)
Avelumab	Merus N.V. (MRUS)
bcg	GH Research PLC (GHRS)
bcg tokyo-172 strain	GH Research PLC (GHRS)
bcg tokyo-172 strain vaccine	GH Research PLC (GHRS)
bgb-a445	BeOne Medicines Ltd. (ONC)
BGB-A445	BeOne Medicines Ltd. (ONC)
Enfortumab Vedotin	Merck & Co., Inc. (MRK)
Eribulin Mesylate	Arbutus Biopharma Corp (ABUS)
incagn02390	Incyte Corp. (INCY)
MK-3120	Merck & Co., Inc. (MRK)
Procarbazine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Sacituzumab Govitecan	Arbutus Biopharma Corp (ABUS)
Supportive care measures	Merck & Co., Inc. (MRK)
Toripalimab	Crinetics Pharmaceuticals, Inc. (CRNX)
ugn-104	UroGen Pharma Ltd. (URGN)
Vinblastine	ASTRAZENECA PLC (AZN)

Phase 2(26)

Drug	Company
9MW2821	Crinetics Pharmaceuticals, Inc. (CRNX)
Arginine hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Avelumab	Structure Therapeutics Inc. (GPCR)
Avelumab	NEKTAR THERAPEUTICS (NKTR)
Copanlisib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
dabogratinib	Tyra Biosciences, Inc. (TYRA)
Dabogratinib TBD	Tyra Biosciences, Inc. (TYRA)
Defactinib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
disitamab vedotin	PFIZER INC (PFE)
Eflornithine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
incagn02385	Incyte Corp. (INCY)
m6223	GH Research PLC (GHRS)
M6223	NEKTAR THERAPEUTICS (NKTR)
Nilotinib Hydrochloride Monohydrate	ENANTA PHARMACEUTICALS INC (ENTA)
nktr-255	GH Research PLC (GHRS)
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Propranolol Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Relatlimab	ENANTA PHARMACEUTICALS INC (ENTA)
sacituzumab govitecan	GH Research PLC (GHRS)
Sacituzumab Govitecan	NEKTAR THERAPEUTICS (NKTR)
TYRA-200	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.125 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.25 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.375 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.50 mg/kg	Tyra Biosciences, Inc. (TYRA)
Vinblastine Sulfate	Assertio Holdings, Inc. (ASRT)

Phase 1(7)

Drug	Company
[225ac]ac-aky-1189	Aktis Oncology Inc. (AKTS)
[64cu]cu-aky-1189	Aktis Oncology Inc. (AKTS)
autologous genetically modified mage a10ᶜ⁷⁹⁶t cells	Adaptimmune Therapeutics PLC (ADAP)
Emavusertib	Amneal Pharmaceuticals, Inc. (AMRX)
Enfortumab Vedotin	ImmunityBio, Inc. (IBRX)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
TYRA-300	Tyra Biosciences, Inc. (TYRA)

Phase 1/Phase 2(2)

Drug	Company
ino-5401	INOVIO PHARMACEUTICALS, INC. (INO)
ino-9012	INOVIO PHARMACEUTICALS, INC. (INO)

Phase 4(2)

Drug	Company
Avelumab	ENANTA PHARMACEUTICALS INC (ENTA)
Enfortumab Vedotin	Fulgent Genetics Inc. (FLGT)

BioSniper tracks 57 drugs in development for Urothelial Carcinoma across 24 companies.

There are 46 clinical trials targeting Urothelial Carcinoma tracked by BioSniper.

The estimated prevalence of Urothelial Carcinoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.